ANEB vs. IMMX, ELDN, TLSA, KZR, CALC, KRON, CARM, EGRX, CKPT, and AEON
Should you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Immix Biopharma (IMMX), Eledon Pharmaceuticals (ELDN), Tiziana Life Sciences (TLSA), Kezar Life Sciences (KZR), CalciMedica (CALC), Kronos Bio (KRON), Carisma Therapeutics (CARM), Eagle Pharmaceuticals (EGRX), Checkpoint Therapeutics (CKPT), and AEON Biopharma (AEON). These companies are all part of the "pharmaceutical preparations" industry.
Immix Biopharma (NASDAQ:IMMX) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, community ranking, valuation, earnings, dividends, analyst recommendations and risk.
Immix Biopharma has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -0.98, meaning that its share price is 198% less volatile than the S&P 500.
11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 55.9% of Immix Biopharma shares are held by insiders. Comparatively, 85.9% of Anebulo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Anebulo Pharmaceuticals' return on equity of -95.00% beat Immix Biopharma's return on equity.
Anebulo Pharmaceuticals received 3 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 87.50% of users gave Anebulo Pharmaceuticals an outperform vote.
Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Immix Biopharma and Immix Biopharma both had 6 articles in the media. Anebulo Pharmaceuticals' average media sentiment score of 1.40 beat Immix Biopharma's score of 0.88 indicating that Immix Biopharma is being referred to more favorably in the media.
Immix Biopharma presently has a consensus target price of $14.00, indicating a potential upside of 466.80%. Anebulo Pharmaceuticals has a consensus target price of $6.67, indicating a potential upside of 189.87%. Given Anebulo Pharmaceuticals' higher possible upside, research analysts clearly believe Immix Biopharma is more favorable than Anebulo Pharmaceuticals.
Summary
Immix Biopharma beats Anebulo Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Anebulo Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anebulo Pharmaceuticals Competitors List
Related Companies and Tools
